<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9111390</journal-id>
<journal-id journal-id-type="pubmed-jr-id">2204</journal-id>
<journal-id journal-id-type="nlm-ta">Eur Neuropsychopharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">Eur Neuropsychopharmacol</journal-id>
<journal-title-group>
<journal-title>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0924-977X</issn>
<issn pub-type="epub">1873-7862</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26706691</article-id>
<article-id pub-id-type="pmc">4762710</article-id>
<article-id pub-id-type="doi">10.1016/j.euroneuro.2015.12.009</article-id>
<article-id pub-id-type="manuscript">NIHMS745866</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Disruption of social cognition in the sub-chronic PCP rat model of schizophrenia: possible involvement of the endocannabinoid system</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Seillier</surname>
<given-names>Alexandre</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Giuffrida</surname>
<given-names>Andrea</given-names>
</name>
</contrib>
<aff id="A1">Department of Pharmacology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78229-3900, USA</aff>
</contrib-group>
<author-notes>
<corresp id="cor1">Corresponding author: Alexandre Seillier, Department of Pharmacology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, Texas 78229-3900, USA, Tel.: +1 210 567 4211 - Fax: +1 210 567 4303, <email>alex.seillier@free.fr</email></corresp>
<fn fn-type="conflict" id="FN3">
<p id="P35">Conflict of interest</p>
<p id="P36">The authors declare no conflict of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>20</day>
<month>12</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="epub">
<day>10</day>
<month>12</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="ppub">
<month>2</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>2</month>
<year>2017</year>
</pub-date>
<volume>26</volume>
<issue>2</issue>
<fpage>298</fpage>
<lpage>309</lpage>
<!--elocation-id from pubmed: 10.1016/j.euroneuro.2015.12.009-->
<abstract>
<p id="P1">Previous studies have shown that social withdrawal in the phencyclidine (PCP) rat model of schizophrenia results from deficient endocannabinoid-induced activation of CB<sub>1</sub> receptors. To understand the underlying cognitive mechanisms of the social deficit in PCP-treated rats, we examined the impact of pharmacological manipulation of the endocannabinoid system on sociability (i.e. social approach) and social novelty preference (which relies on social recognition).</p>
<p id="P2">Control rats showed a clear preference for a “social” cage (i.e. unfamiliar stimulus rat placed under a wire mesh cage) versus an “empty” cage, and spent more time exploring a “novel” cage (i.e. new stimulus rat) versus a “familiar” cage. In contrast, rats receiving PCP (5 mg/kg, b.i.d. for 7 days, followed by a 7 day-washout period) showed intact sociability, but lacked social novelty preference. This PCP-induced deficit was due to increased activity at CB<sub>1</sub> receptors as it was reversed by systemic administration of the CB<sub>1</sub> antagonist AM251 (1 mg/kg). In agreement with this hypothesis, the cannabinoid agonist CP55,940 (0.003 – 0.03 mg/kg) dose-dependently suppressed social novelty preference in control animals without affecting sociability.</p>
<p id="P3">Taken together, these data suggest that PCP-treated rats have a deficit in social cognition, possibly induced by increased stimulation of CB<sub>1</sub> receptors. This deficit, however, is distinct from the social withdrawal previously observed in these animals, as the latter is due to deficient, rather than increased, CB<sub>1</sub> stimulation.</p>
</abstract>
<kwd-group>
<kwd>endocannabinoid</kwd>
<kwd>odor discrimination</kwd>
<kwd>phencyclidine</kwd>
<kwd>social cognition</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>